Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Number of items: 4.

Beresford, Mark, Casbard, Angela ORCID:, Hudson, Zoe, Carucci, Margherita, Ingarfield, Kate, Gee, Julia ORCID:, Smith, Joanna ORCID:, Kitson, Terri ORCID:, Alchami, Fouad, Madden, Tracie-Ann ORCID:, Hayward, Larrie, Hwang, David, Spensley, Saiqa, Waters, Simon, Wheatley, Duncan and Jones, Robert H. ORCID: 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1 (1) , 13. 10.1038/s44276-023-00016-8

Jayson, G., Carucci, Margherita, Hurt, Christopher ORCID:, Zhou, Cong, Monaghan, Phillip, Wych, Julie, Irving, Alys, Narasimham, Monica, Morrison, Hilary, Campbell, Sue, Glasspool, Rosalind, Longo, Mirella ORCID:, Nelson, Annmarie ORCID:, Dive, Caroline, Adams, Richard ORCID: and Clamp, Andrew 2021. VALTIVE1: Validation of Tie2 as a response biomarker for VEGF inhibitors In Ovarian Cancer. Presented at: NCRI Cancer Conference, 2021.

Jones, Robert H. ORCID:, Casbard, Angela ORCID:, Carucci, Margherita, Cox, Catrin, Butler, Rachel, Alchami, Fouad, Madden, Tracie-Ann ORCID:, Bale, Catherine, Bezecny, Pavel, Joffe, Johnathan, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, Foxley, Andrew and Howell, Sacha J. 2020. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology 21 (3) , pp. 345-347. 10.1016/S1470-2045(19)30817-4

Hurt, Christopher N. ORCID:, Jones, Sadie E. F., Madden, Tracie-Ann ORCID:, Fiander, Alison, Nordin, Andrew J., Naik, Raj, Powell, Ned, Carucci, Margherita and Tristram, Amanda 2018. Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multi-centre, randomised, phase II trial (RT3VIN). BJOG: An International Journal of Obstetrics and Gynaecology 125 (9) , pp. 1171-1177. 10.1111/1471-0528.15124

This list was generated on Sun Apr 21 06:15:46 2024 BST.